Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease
Jeremy Liu Chen Kiow(University of British Columbia), Greg Rosenfeld(British Columbia Centre on Substance Use), Yvette Leung(University of Calgary), Brian Bressler(University of British Columbia), Daniel Rosenfeld(Hebrew University of Jerusalem), Harjot Bedi(University of British Columbia), Thomas Hoang(University of British Columbia), Zhina Majdzadeh Ardekani(University of British Columbia), Marica Reise-Filteau(University of British Columbia)
Cited by 9
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Smoking Rain Clouds over the Amazon
|Science|2004|1.7k
Persistent sulfate formation from London Fog to Chinese haze
|Proceedings of the National Academy of Sciences|2016|1.6k